Pacific Biosciences Of California Stock Earnings Reports

Q1 2026 highlights: PacBio reported flat total revenue of $37.2M with record consumables revenue of $21.8M (up 9% YoY) and >100% YoY growth in consumable shipments to clinical accounts. Clinical shipments now represent mid-teens percent of total consumable shipments and are accelerating as customers move from validation to commercialization. Instrument performance was mixed: Revio shipments increased (15 units in Q1) with continued multi-system and new-customer demand, while Vega revenue was pressured by softer U.S. academic funding and a temporary Q1 promotion that compressed ASPs and margins. EMEA was the strongest region (+17% YoY) driven by clinical/rare disease adoption; Asia Pacific declined as some customers awaited the SPRQ-Nx commercial launch. Strategic progress includes the imminent SPRQ-Nx commercial launch (expected later this month) — positioned to improve throughput, multi-use SMRT Cell economics and drive both instrument and consumable demand — and the Basecamp Research collaboration to sequence ~100,000 metagenomic samples toward a "Trillion Gene Atlas." The company closed the sale of short-read assets to Illumina, receiving ~$48.1M net proceeds, ending Q1 with ~$276M in unrestricted cash. Margin headwinds in Q1 were driven by rising compute/memory costs, the Vega promotion, and one-time items; management expects gross margins to improve in Q2 but now projects more modest margin expansion for 2026. PacBio lowered the high end of its 2026 revenue guide by $5M to $165M–$175M and expects non-GAAP operating expenses of $220M–$225M, with operating expense reductions year-over-year.